Change of Adviser
20 May 2020
Redx Pharma plc
("Redx" or "the Company")
Change of Adviser
The Company announces that SPARK Advisory Partners Limited has been appointed as the Company's nominated adviser with immediate effect.
|
For further information, please contact: |
|
|
|
|
|
Redx Pharma Plc |
T: +44 1625 469 918 |
|
Iain Ross, Chairman Lisa Anson, Chief Executive |
|
|
|
|
|
SPARK Advisory Partners Limited (Nominated Adviser) |
T: +44 203 368 3550 |
|
Matt Davis/Andrew Emmott |
|
|
|
|
|
WG Partners LLP (Broker) |
T: +44 20 3705 9330 |
|
Claes Spång/Chris Lee/David Wilson |
|
|
|
|
|
FTI Consulting |
T: +44 20 3727 1000 |
|
Simon Conway/Ciara Martin |
|
|
|
|
About Redx Pharma Plc
Redx is a UK based biotechnology company whose shares are traded on AIM (AIM:REDX). Redx's vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.
If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts/
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Latest directors dealings
- 8 minutes ago BAE Systems
- 1 hour ago Ocado Group
- 2 hours ago Aviva
- 2 hours ago Lancashire Holdings Limited
- 2 hours ago Kingfisher